Plasma Triglyceride-Rich Lipoprotein and High Density Lipoproteins Disorders Associated with Atherosclerosis

Journal of Investigative Medicine

Volumn 46, Issue 8, 1998, Pages 351-358

  Genest Jr , Jacques ^a   Cohn, Jeffrey ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTERIOSCLEROSIS; BLOOD; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; GENETICS; HUMAN; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; CORONARY DISEASE; EPIDEMIOLOGIC STUDIES; HUMANS; LIPOPROTEINS, HDL; RISK FACTORS; TRIGLYCERIDES;

EID: 0032186157     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
2. Steiner A, Domaski B. Serum cholesterol level in coronary arteriosclerosis. Arch Intern Med 1943;71 :397-402.
3. Master AM, Dack S, Jaffe HL. Age, sex and hypertension in myocardial infarction due to coronary occlusion. Arch Intern Med 1939;64:767-786.
4. Keys A. Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.
5. Dawber TR. The Framingham study; the epidemiology of atherosclerotic disease. Cambridge: Harvard University Press; 1980.
6. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Ross Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wayne Warnica J et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 1996;335:1001-9.
9. Schmitz G, Assmann G. Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: Scriver CR, Beaudet, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill 1989;1623-44.
10. Spence MW, Callahan JW. Sphingomyelin-cholesterol lipidoses: the Niemann-Pick group of diseases. In: Scriver CR, Beaudet, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill 1989;1655-76.
11. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill 1989;1139-64.
12. Wetterau JR, Aggerbeck LP, Bouma M-E, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258:999-1001.
13. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. New York-McGraw-Hill 1989;1165-80.
14. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
15. Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol 1975;102:514-525.
16. Toor M, Katchalsky A, Agmon J. Atherosclerosis and related factors in immigrants to Israel. Circulation 1960;22:265-79.
17. Kushi LH, Lew RA, Stare FJ, Ellison CR, el Lozy M, Bourke G, Daly L, Graham I, Hickey N, Mulcahy R. Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. N Engl J Med 1985;312:811-8.
18. Rosenman RH, Friedman M, Straus R. Wurm M, Kositchek R. Hahn W, Worth essen NT. A predictive study of coronary heart disease. The Western Collaborative Group study. JAMA 1964;189:15-26.
19. Shekelle RB, Shryock AM, Paul O, Lepper M, Stamler J. Liu S, Raynor WJ Jr. Diet, serum cholesterol, and death from coronary heart disease: The Western Electric study. N Engl J Med 1981;304:65-70.
20. Holme I, Solberg LA, Weissfeld L, Helgeland A, Hjermann I, Leren P, Strong JP, Williams OD. Coronary risk factors and their pathway of action through coronary raised lesions, coronary stenoses, and coronary death. Multivariate statistical analysis of an autopsy series; the Oslo study. Am J Cardiol 1985;55:40-7.
21. Reed D, Yano K, Kagan A. Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer in the Honolulu Heart Program. Am J Med 1986;80:871-8.
22. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982;248:1465-77.
23. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981;141:1128-31.
24. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835-8.
25. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987;257:2176-80.
26. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977;62:707-14.
27. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983;52:98-128.
28. Havel RJ, Kane JP. Structure and metabolism of plasma lipoproteins. In: CR Scriver, AL Beaudet, WS Sly, D Valle, eds. The metabolic and molecular basis of inherited disease. 7th edition. New York: McGraw-Hill, USA 1995:1841-51.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentraion of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-503.
30. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-70.
31. Avins AL, Haber RJ, Hulley SB. The status of hypertriglyceridemia as a risk factor for coronary heart disease. In: Rifkind BM, Lippel K, eds. Clinics in laboratory medicine 1989;9:153-68.
32. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:1-14.
33. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
34. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209.
35. Castelli WP. Epidemiology of triglycerides. A view from Framingham. Am J Cardiol 1992;70:3H.
36. Fontbonne E, Eschwege E, Cambien F, Richard J-L, Ducimetiere P, Thibult N, Warnet J-M, Claude J-R, Rosselin G-E. Hypertriglyceridema as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 1989;32:300-4.
37. Uusitupa MIJ, Niskanen LK, Siitonen O. Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (noninsulin-dependent) diabetic and nondiabetic subjects. Diabetologia 1993;36:1175-84.
38. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30.
39. Smith SJ, Cooper GR, Myers GL, Sampson EJ. Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values. Clin Chem 1993;39:1012-22.
40. Bradley WA, Gianturco SH. Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations. J Intern Med 1994;236:33-9.
41. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1991;37:249-73.
42. Weber M, McNicoll S, Lussier-Cacan S, Marcil M, Connelly P, Rondeau C, Latour Y, Davignon J, Genest J Jr. Plasma lipoproteins, apolipoprotein B, apolipoprotein E phenotypes and metabolic factors in premature CAD in French Canadians. Can J Cardiol 1997;13:253-60.
43. Scheafer EJ, Lery RI, Anderson DW, Danner RN, Brewer HB Jr, Blackwelder WC. Plasma triglycerides in the regulation of HDL. Lancet 1978;2:391-393.
44. Patsch JR, Miesenböck G, Hopferwieser T, Möhlberger V, Knapp E, Dunn JK, Gotto AM JR, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336-45.
45. Stampfer MJ, Krauss RM, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
46. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagné SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;335:848-54.
47. Nikkilä EA. Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolish. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease. 5th edition. New York: McGraw-Hill, 1983;622-42.
48. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976;25:313-20.
49. Brunzell JD, Alberss JJ, Chait A, Gruncy SM, Grozek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147-55.
50. Austin MA, McKnight B, Edwards KL, Wallace KJ, Bradley CM, McNeely MJ, Brunzell JD, Motulsky AG. Twenty-year cardiovascular disease (CVD) mortality in familial combined hyperlipidemia and familial hypertriglyceridemia: an historical cohort study [abstract]. Circulation 1997;96:1-412.
51. Chait A, Brazg RL, Tribble Dl, Krauss RM. Susceptibility of small, dense low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
52. Mahley RW, Rail SC, Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. New York: McGraw-Hill Publishing Co 1989:1195-213.
53. Genest J Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner JL, Meyers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
54. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977;62:707-14.
55. Jacobs DR (for Lipid Research Clinics Follow-Up Study). High density lipoprotein cholesterol and coronary heart disease, cardiovascular disease and all-cause mortality. Circulation 1985;72(III Suppl):185.
56. Watkins LO, Neaton JD, Kuller LH. Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the multiple rish factor interverntion trial. Am J Cardiol 1986;57:538-45.
57. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart disease: a prospective case-control study. Lancet 1977;1:965-8.
58. Goldbourt U, Medalie JH. High-density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli ischemic heart disease study. Am J Epidemiol 1979;109:296-308.
59. Enger SC, Hjermann I, Foss OP, Helgeland A, Holme I. Leren P, Norum KR. High-density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery 1979;5:170-81.
60. Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary hearth disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11-S20.
61. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1986;79:8-15.
62. Wilson PWF, Abbott RD, Castelli WP, High density lipoprotein cholesterol and mortality. The Framingham study. Arteriosclerosis 1988;8:737-41.
63. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17;107-13.
64. Robinson D, Ferns GA, Bevan EA, Stocks J, Williams PT, Gratton DJ. High density lipoprotein subfractions and coronary risk factors in normal men. Arteriosclerosis 1987;7:341-6
65. Stampfer MJ, Sacks FM, Salvini S. W'llett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J med 1991;325:373-81.
66. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotien phenotype: a proposed genetic marker for coronary heart disease rik. Circulation 1990;82:495-506.
67. Genest J Jr, Bard J-M, Fruchart J-C, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb 1993;13:1728-37.
68. Dammerrnan M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation 1995;91:505-11.
69. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS and Valle D, eds. The metabolic and molecular basis of inherited disease. 7th edition. McGraw-Hill, USA 1995: 2031-52
70. Calabresi L, Francescini G. High density lipoprotein and coronary artery disease: insights from mutations leading to low density lipoprotein. Curr Opinion Lipidol 1997;8:219-24.
71. th edition. McGraw-Hill, USA 1995:2053-72.
72. Serfaty-Lacrosniere C, Civiera F, Lanzberg A et al. homozygous Tangier disease and coardiovascular disease. Atherosclerosis 1994;107:85-98.
73. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997;38:191-205.